SEC Form 4 · accession 0000929638-26-002260
enGene Therapeutics Inc. · ENGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Grossman
Officer — Interim Chief Medical Officer · Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 5:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001980845
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.75 | Jun 16, 2026 | A | 31,000 | A | — | Jun 16, 2036 | Common Shares | 31,000 | 31,000 | D |
| Stock Option (Right to Buy)F2 | $1.75 | Jun 16, 2026 | A | 200,000 | A | — | Jun 16, 2036 | Common Shares | 200,000 | 200,000 | D |
Explanation of responses
- F1This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board.
- F2This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company.